Fibrotic interstitial lung diseases comprise a diverse group of disorders that progressively destroy the delicate tissue of the lung parenchyma. Idiopathic pulmonary fibrosis, the archetypal member of this family, is almost always progressive, characterized by worsening breathlessness, a steady loss of lung capacity, and ultimately respiratory failure and death. Other interstitial lung diseases, including those driven by autoimmune conditions, hypersensitivity reactions, or occupational exposures, may also evolve into a progressive fibrotic phenotype, now termed progressive pulmonary fibrosis, which shares much of the grim natural history of idiopathic pulmonary fibrosis. Before the arrival of antifibrotic drugs, therapeutic options were limited, and median survival after diagnosis was measured in just a few years.

Weight loss and malnutrition have long been recognized as poor prognostic markers in chronic lung disease. In chronic obstructive pulmonary disease, for example, dietary supplementation in malnourished patients has been shown to improve exercise capacity, respiratory function, and health-related quality of life. The role of nutrition in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis has been far less well understood, in part because body weight in these patients can be influenced by many competing forces. Reduced exercise tolerance and corticosteroid use may push weight upward, while disease symptoms and medication side effects can suppress appetite and drive unintended loss. Studies vary widely in reported malnutrition prevalence, but a consistent finding has emerged across cohorts: unintentional weight loss is associated with worse outcomes.

The evidence is striking. Japanese and United Kingdom cohort studies in idiopathic pulmonary fibrosis demonstrated that an annual body weight loss of 6.1 percent predicted lower survival, even in patients in whom a decline in forced vital capacity, the standard measure of lung function, was not observed. A Danish survey of one hundred patients found that those reporting unintentional weight loss of at least five percent of body weight at baseline faced significantly higher risks of mortality and hospital admission within a year. In a multicentre study, both body mass index and weight loss were independently associated with one-year mortality in fibrotic interstitial lung disease. A meta-analysis of thirty-four studies encompassing more than eighteen thousand patients confirmed that low baseline body mass index and weight loss during the disease course were independent predictors of mortality.

To explore these relationships in the context of modern therapy, the review authors examined data from the pivotal Phase III trials of nintedanib. The INPULSIS program randomized 1,066 patients with idiopathic pulmonary fibrosis to nintedanib 150 mg twice daily or placebo, reporting annual rates of forced vital capacity decline of minus 239.9 milliliters and minus 207.3 milliliters in the placebo arms, which improved to minus 114.7 and minus 113.6 milliliters respectively with treatment. A pooled analysis demonstrated an overall reduction in the annual rate of decline of 109.9 milliliters with nintedanib. The INBUILD trial similarly randomized 663 patients with progressive fibrosing interstitial lung disease to the same treatment regimen. Crucially, both trials collected detailed data on baseline body mass index and weight change over fifty-two weeks, allowing investigators to stratify outcomes by nutritional status.

The findings from the placebo arms paint a consistent picture. Patients with lower body mass index, below 25 kilograms per square meter, experienced numerically greater annual decline in forced vital capacity than those in the mid-range of 25 to under 30 or the obese range of 30 and above. Likewise, patients who lost more than five percent of their body weight over the trial year declined faster than those who lost less or gained weight. Adverse associations extended to other endpoints as well, with lower baseline body mass index and unintended weight loss both linked to poorer outcomes overall. The new and previously unpublished analyses of pooled INPULSIS data added an important refinement: the deleterious effect of weight loss on lung function was most pronounced in patients who started with a body mass index below 25, was still evident in those in the overweight range who lost more than five percent of body weight, and was not observed at all in patients with obesity.

The relationship between weight loss, lung decline, and mortality proved complex rather than linear. In the INPULSIS placebo arm, patients losing more than five percent of body weight had numerically fewer deaths than those with lesser weight change, a finding the authors caution was based on exploratory analyses with limited events and was not powered for mortality comparisons. In INBUILD, by contrast, a four-kilogram weight decrease corresponded to an increased risk of acute exacerbation or death in multivariable analysis, though not to a greater risk of disease progression. These discordances likely reflect the multifactorial nature of mortality in fibrotic lung disease, differences in baseline characteristics between populations, and the fact that forced vital capacity decline and death capture related but distinct dimensions of disease severity.

A central question hovered over the entire analysis: because nintedanib itself commonly causes gastrointestinal side effects, including diarrhoea, nausea, and appetite loss, could treatment-induced weight loss undermine the drug’s benefits? The data emphatically answer no. Weight loss exceeding five percent over fifty-two weeks occurred in 37.8 percent of nintedanib-treated patients in INPULSIS compared with 20.1 percent on placebo, and in 55 percent of nintedanib patients in INBUILD versus 39 percent on placebo. Yet in the nintedanib arms, the rate of forced vital capacity decline was similar between patients with and without significant weight loss, at roughly 103 versus 121 milliliters per year, and the treatment effect versus placebo was preserved across every body mass index subgroup. Indeed, the greatest benefit was observed in patients with lower body mass index and those experiencing weight loss, suggesting the antifibrotic effect operates independently of nutritional status.

The review also situates these findings within a broader body composition literature that moves beyond simple scales. Body mass index cannot distinguish fat mass from lean mass, and recent work indicates that lung function in fibrotic disease correlates with muscle quantity and quality, with sarcopenia associated with poor prognosis. Fat-free mass index has been significantly correlated with survival in idiopathic pulmonary fibrosis, the Geriatric Nutritional Risk Index predicts both prognosis and antifibrotic continuation rates, and bioimpedance-derived phase angle outperformed traditional measures in discriminating patients with worse lung function and quality of life. Measures of skeletal muscle attenuation have been associated with lung function and functional capacity, underscoring that not all weight loss carries the same physiological meaning.

The authors conclude that nutritional advice and weight monitoring should form an integral component of supportive care, with targeted strategies aimed at patients at highest risk, particularly those with low baseline body mass index who subsequently lose weight. Practical recommendations include increasing protein intake, eating smaller and more frequent meals to counteract appetite loss, and maintaining hydration to manage gastrointestinal toxicities, while adherence to a Mediterranean diet has been associated with improved lung function in related populations. A recent pilot randomized controlled trial demonstrated that specialist dietary intervention is feasible in patients experiencing unintentional weight loss, though definitive evidence that nutrition directly modifies long-term outcomes remains limited. Most importantly, the findings reinforce a message for patients and clinicians alike: rather than discontinuing antifibrotic therapy when gastrointestinal effects and weight loss emerge, every effort should be made to manage these side effects and maintain adherence, because the preservation of lung function that these drugs deliver outweighs the metabolic cost, and the antifibrotic shield holds firm regardless of what the scale says.

Subject of Research: The impact of weight loss and body mass index on outcomes in nintedanib clinical trials for interstitial lung disease.

Article Title: Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease

Article References: Kreuter, M., Kottmann, R. M., Luo, F., Coeck, C., Kanakapura, M., Schlecker, C., Ritter, I., & Handa, T. (2026). Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease. Advances in Therapy. https://doi.org/10.1007/s12325-026-03785-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03785-z

Keywords: nintedanib, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, weight loss, body mass index, interstitial lung disease, forced vital capacity, antifibrotic therapy, malnutrition, nutrition, INPULSIS, INBUILD

The study, conducted by Sun, Li, Ping and their colleagues, delves into the landscapes of human lung tissue recovered from individuals with a history of TB. By scrutinizing 19 post-tuberculosis lung samples along with 13 matched normal lung tissues used as controls, they journey beyond conventional bulk analysis towards an intricate, cell-by-cell exploration. Their approach zeroes in on the microenvironments within and immediately surrounding residual tuberculosis lesions, aiming to decode the molecular footprints that linger after the bacteria’s defeat.

Among the striking revelations of this investigation is the identification of a consistent molecular signature echoing across multiple lung cell populations. This signature weaves a complex tapestry of cellular senescence, chronic inflammation, progressive fibrosis, and apoptotic signaling—processes that collectively choreograph the decline of lung architecture and function. Notably, this study uncovers an elevation in vascular inflammation as a pivotal hallmark of post-tuberculosis lung pathology, suggesting that the blood vessel lining cells play a critical role in the long-term damage.

Dissecting the transcriptional profiles reveals a coordinated suppression of FOXO3 signaling pathways alongside amplification of NF-κB-driven thromboinflammatory responses. FOXO3, a transcription factor broadly implicated in longevity and cellular stress resistance, emerges here as a guardian diminished in its protective capacity. Conversely, activation of NF-κB, a notorious regulator of inflammatory gene networks, fuels a prothrombotic and inflammatory milieu that likely perpetuates tissue injury long after the initial infection subsides.

The investigators validate these transcriptomic observations through functional assays that manipulate the endothelial cells lining pulmonary blood vessels. By silencing FOXO3 via small interfering RNA and administering thrombin—a key coagulation protein—they experimentally recapitulate enhanced cellular senescence and inflammatory responses. This experimental validation underscores the mechanistic axis linking reduced FOXO3 activity and thrombin-driven NF-κB activation to ongoing endothelial dysfunction and tissue degeneration.

Such endothelial dysfunction and vascular inflammation have profound implications for lung health. The fine capillary networks essential for gas exchange appear compromised, setting the stage for hypoxia, impaired tissue repair, and relentless fibrotic remodeling. Senescent endothelial cells adopt a pro-inflammatory secretory phenotype that further recruits immune cells and amplifies local damage, creating a vicious cycle of persistent injury.

The impact of chronic inflammation and fibrogenesis following tuberculosis extends beyond localized tissue destruction. Distorted lung mechanics and stiffened extracellular matrices impair respiratory compliance, often explaining why patients continue to suffer breathlessness, cough, and diminished quality of life despite microbiological cure. This study’s insights into the molecular drivers of these changes offer promising avenues for precision therapies aimed at halting or even reversing lung impairment after TB.

By charting the single-cell transcriptomic atlas of the post-tuberculosis lung, this work provides an unprecedented resolution into the heterogeneous cellular ecosystem affected by TB. It highlights not merely the immune cells but also structural and endothelial cells as active participants in disease perpetuation. The complex interplay between senescence signaling, inflammatory cascades, and vascular pathology emerges as a central theme warranting further clinical exploration.

Moreover, the findings challenge the traditional focus on antibacterial treatment as the sole solution for tuberculosis morbidity. They spotlight the necessity of targeting the host tissue responses that outlive the pathogen, particularly those that orchestrate irreversible tissue damage. Efforts to modulate FOXO3 signaling or interrupt thromboinflammation could form the basis of adjunctive therapies designed to restore lung function and prevent progression to chronic respiratory failure.

The repercussions extend to global health landscapes where tuberculosis remains endemic. Millions survive TB each year, yet many face long-term disability attributable to lung sequelae. Understanding and intervening in the molecular cascades identified here could improve patient outcomes, reduce the burden on healthcare systems, and elevate quality of life for TB survivors worldwide.

This research also exemplifies the power of single-cell transcriptomics as an investigative tool in infectious disease sequelae, revealing nuances that bulk tissue analyses cannot resolve. By mapping gene expression profiles at cellular resolution, scientists can unravel complex pathologies and identify precise cellular targets with therapeutic potential.

The complex nexus between reduced FOXO3 activity and thrombin-mediated NF-κB activation delineated in this study sheds light on convergent pathways that could be exploited pharmacologically. FOXO3 activators or NF-κB inhibitors might be combined with anticoagulants or anti-fibrotic agents in innovative regimens tailored toward halting the progression of post-infectious lung fibrosis.

While challenges remain, including translating these molecular insights into safe and effective clinical interventions, this study lays a foundational framework. The next phase of research will likely focus on in vivo validation using animal models and clinical trials to evaluate agents that restore endothelial health and quell aberrant inflammation in post-tuberculosis lungs.

In sum, the work by Sun and colleagues presents a transformative step forward in understanding the cellular and molecular choreography underpinning the chronic pulmonary damage seen after TB infection. It opens new horizons for therapeutic innovation that could redefine care for millions affected by this ancient yet persistently devastating disease.

Subject of Research: Post-tuberculosis pulmonary damage mechanisms analyzed via single-cell transcriptomics.

Article Title: A single-cell transcriptomic atlas reveals senescence and inflammation in the post-tuberculosis human lung.

Article References:
Sun, G., Li, K., Ping, J. et al. A single-cell transcriptomic atlas reveals senescence and inflammation in the post-tuberculosis human lung. Nat Microbiol (2025). https://doi.org/10.1038/s41564-025-02050-3

Image Credits: AI Generated